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unadjusted P¼0.018 adjusted; Fig 1 a & b). No interactions were
determined for SPD, SPM or the total polyamine concentration. There
was no difference observed between ROA and no ROA for any of the
polyamines or the total polyamine concentration (PUT P¼0.801, SPD
P¼0.838, SPM P¼ 0.853, total polyamine concentration P¼0.795).
Conclusions: This pilot study indicated that measurement of polyamine
concentrations in plasma of volunteers with osteoarthritis is reprodu-
cible. Few studies investigating polyamine concentrations in OA have
been performed previously and ours is the ﬁrst study to utilise plasma
samples to determine systemic plasma concentrations in OA. Our data
suggest that there are a number of different OA phenotypes, particularly
highlighted by the differences between hip and knee OA. Further study
of polyamine concentrations in OA needs to be carried out with larger
numbers of patients.
Figure 1. Analysis of polyamine concentrations in plasma samples from
volunteers with varying degrees of osteoarthritis severity, divided by
affected joint.
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CCL3 AS SERUM BIOMARKER IN PATIENTS WITH KNEE
OSTEOARTHITIS: A CROSS-SECTIONAL STUDY
Z. Zhang, X. Zhao, W. Liao. First afﬁliated Hosp. of Sun Yat-sen Univ,
Guangzhou, China
Purpose: Inﬂammation is widely accepted to be an essential part of
osteoarthritis, chemokines as mediators of chemoattraction (chemo-
taxis) are known to play a pivotal role in this process. However, its role
in osteoarthritis biomarker is rarely reported. The aim of this cross-
sectional study is to explore the ability of chemokines in serum to
identify the degree of knee osteoarthritis.
Methods: There are altogether 284 knee healthy subjects and 338 osteo-
arthritis patients participated in this project between September, 2012 and
December, 2013. According to the inclusion and exclusion criteria, 47 early
and59 later knee osteoarthritis patients and 75 knee healthy subjectswere
ﬁnally enrolled. Samples were collected prior to any treatment. The
promising chemokines, CCL3, CCL4, CXCL1 and CXCL8/ IL8, and four well
studied proinﬂammatory cytokines, IL1b, IL6, TNFa and resistin, were
quantiﬁed using suspension array. Preoperative radiography, magnetic
resonance imaging and arthroscopy ﬁndings were compared with sus-
pensionarray results.And theoutcomeswerepresented ina statisticalway.
Results: In all serum chemokines and cytokines tested, serum CCL3 and
IL8 were the two best predictors of early osteoarthritis occurred (area
under the curve ¼0.769 and 0.765, respectively). Serum CCL3 was
highly speciﬁcity to early knee osteoarthritis, especially to pre-radiog-
raphy patients, whereas serum IL8 showed low speciﬁcity but high
sensitivity. Signiﬁcant difference in serum CXCL1, IL8, CCL3, CCL4 and
resistin were presented among knee OA patients with different KL
grades. Although the difference did not meet statistical signiﬁcance,
elevated CCL3, CCL4 levels in serumwere associated with the severity of
high burden knee osteoarthritis. Additional, test results from suspen-
sion array were corrected well with those from ELISA.Conclusions: Serum IL8 was a promising diagnostic biomarker for early
knee osteoarthritis. And serum CCL4 was suggested can give well
reﬂection on burden of knee osteoarthritis. Serum CCL3, moreover, was
performed excellent in both sides.
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ESTABLISHING A KNEE PRESERVATION REGISTRY TO FOLLOW
PATIENTS WITH DEGENERATIVE JOINT DISEASE
A. Szulc, H. Murphy, C.K. Nathasingh, E. Lee, A. Payne, I. Inneh,
H.-G. Wisniewski, R. Iorio, L. Jazrawi, J. Slover, J. Samuels, E.J. Strauss,
P.A. Band. NYU-Hosp. for Joint Disease, New York, NY, USA
Purpose: The Joint Preservation Registry (JPR) is a prospective, pragmatic,
observational study, designed to identify clinical and biochemical markers
of osteoarthritis (OA) phenotype, status and progression. Because the time
course of degenerative joint disease is highly variable, the optimal treat-
ment for an individual patient is clinically determined by multiple factors,
and highly variable between both clinicians and patients. Few large data
sets are available studying theways that clinicians andpatients handle this
uncertainty, particularlywith respect to the timingof surgical intervention.
To address this gap in knowledge, the JPR was established to follow con-
senting patients who present with knee symptoms to physicians at the
center for musculoskeletal care of a large tertiary care medical center. The
JPR also is intended to evaluate whether synovial ﬂuid biomarkers pre-
viously found to be predictive of radiologic progression and knee replace-
mentovera3-yearperiod, are alsopredictiveofpain scoreprogressionover
shorter time periods, and useful for optimizing treatment pathways.
Methods: Patients presenting with knee-related complaints were
recruited into a Knee Preservation Registry, asked to consent to regular
follow-up by email or phone every 6-12 months, and to allow any bio-
specimens collected during the course of their standard care to be
retained in a bio-repository for future analyses. Participating inves-
tigators included both physicians and surgeons from the divisions of
Sports Medicine, Rheumatology, and Adult Reconstruction. Inclusion
criteria were deliberately broad to enable a diverse patient population,
ranging from recent acute injury to advanced degenerative disease, and
including patients with comorbidities. The registry is observational and
captures demographics, medical history, anthropometrics, diagnosis
codes, treatments, imaging, and patient-reported outcome (PRO), with
much of the data directly retrieved from the medical record. Synovial
ﬂuid (SF) biomarker analysis and PRO score collection at regular follow-
up are the only study-related procedures. Patients will be followed for 5
years from the time of enrollment.
Results: From September 2012 to July 2014, 813 patients (M ¼ 340, F ¼
473) were recruited for the registry. The average age at enrollment was
52.3 years. SF was aspirated from 167 subjects (225 knees, 57 bilateral,
111 unilateral), for a total of 302 unique SF samples in the current bio-
repository which represents 21% of the total population that was
sampled. The same percentage of patients with effusionwas noted to be
the same (21%) among men and women. Distribution of diagnoses,
deﬁned by ICD-9, was 72% for osteoarthritis (OA), 10% for acute injuries,
and 18% for other non-OA complaints. Approximately half of the
enrolled patients have reached the 6-12 month follow-up.
Conclusions: To our knowledge, this is the ﬁrst pragmatic registry for
knee OA patients that are not scheduled for knee replacement. The
information captured by our registry can be used to study disease phe-
notypes as they relate to treatment alternatives, including ethnic, racial,
socioeconomic and gender disparities. Ultimately we hope to establish
evidence-based treatment pathways using a combination of biomarkers,
PRO scores and advanced imaging to customize the treatment of OA to
individual patient needs and preferences, and to assist surgeons in
determining the appropriate timing for joint replacement.
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SEGREGATING OA PATIENTS WITH AND WITHOUT JOINT
INFLAMMATION USING TWO BIOMARKERS OF CONNECTIVE TISSUE
INFLAMMATION
A.-C. Bay-Jensen, I. Byrjalsen, A. Bihlet, K. Musa, B.J. Riis,
C. Christiansen, M.A. Karsdal. Nordic BioSci. A/S, Herlev, Denmark
Purpose: We have recently identiﬁed the presence fragments of CRP,
generatedbymatrixmetalloproteinases (MMPs). C-reactive protein (CRP)
is an acute phase reactant, involved in both acute and chronic inﬂam-
matory diseases. CRP is producedmainly by the liver upon elevated levels
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inﬂamed tissue where it binds its receptors and thereby accumulated by
the tissue. These fragments are released from the tissue as MMPs are
upregulated in response to pro-inﬂammatory induction. C3M is a bio-
marker of type II collagen remodeling,which is released from the synovial
membranewith inducedwithpro-inﬂammatorycytokines. The aimof the
studywas to investigatewhether the level of theproteinﬁngerprintCRPM
together with the tissue turnover biomarker C3M could segregate OA
patients with and without inﬂammatory arthritis.
Methods: CRPM and C3M were measured in the serum of knee OA
patients taking part of the two phase III RCTs (NCT00486434 and
NCT00704847). Baseline and 2 year follow-up pain questionnaires and
radiography were recorded for each patient. An array of additional bio-
markers were measure; C1M, C2M, CTX-II, CTX-I and osteocalcin. The
biomarkers were plotted against each other (ﬁgure) and cut-offs were set
based on reference value and difference between clinical measures and
biomarkers in the two patient groups were analyzed by Mann-Whitney.
Results: Patients were separated into 2 groups; 1) patient with low
CRPM and low C3M, and 2) patients with either high CRPM or high C3M,
or with both high. 16% of the patients were found group 2. Several of the
measures were higher in group 2: Cartilage degradation (C2M) and
connective tissue degradation (C1M) were signiﬁcantly higher
(p¼0.0037, p<0.0001, respectively), as well as WOMAC subscale ques-
tion Q5 (p¼0.0191). There was no group difference in KL score or JSW
nor in CTX-I, CTX-II and osteocalcin. Group 1 patients (low in both CRPM
and C3M) progressed structurally more group 1 patients (p¼0.046).
Conclusions:We found that different of the two inﬂammatory markers
could facilitate patient segregation. This may have many implications,
however most importantly in the identiﬁcation of more OA patients
with the right diagnosis, inﬂammatory vs. non-inﬂammatory disease,
which may beneﬁt from a given treatment.117
INTRAARTICULAR INJECTION OF ADIPOSE MESENCHYMAL STEM
CELLS OVER HYALURONIC ACID AND COLLAGEN TYPE II CLEAVAGE
NEOEPITOPE IN THE TREATMENT OF OSTEOARTHRITIS IN DOGS
M. Rubio Zaragoza y,z, B. Cuervo Serrato y,z, J. J. Sopena Juncosa y,z,
R. Cugat Bertomeu x,z, A. Tvarijonaviciute x, J. J. Ceron Madrigal ¶,
J. M. Carrillo Poveda y,z. yUniv. CEU Cardenal Herrera, Alfara del Patriarca,
Spain; zGarcia Cugat Fndn., Barcelona, Spain; xArtroscopia GC, Barcelona,
Spain; kUniv. Murcia, Espinardo, Spain; ¶Univ. de Murcia, Espinardo,
Spain
Purpose: Osteoarthritis (OA) is a very common degenerative disease
affecting the articular cartilage in both human and veterinary
medicine.
While conventional treatments like physiotherapy or drugs offer tem-
porary relief of clinical symptoms, restoration of normal cartilage
function has been difﬁcult to achieve. Moreover, in severe cases of
osteoarthritis total articular replacement may be required.
The regenerative medicine offers exciting possibilities for treating OA.
The mesenchymal stem cells are candidates for use in this pathology
because they offer exciting possibilities to differentiate into other tissue
lineages, and have signiﬁcant effects on regeneration and/or main-
tenance of articular cartilage, reducing pain and increasing the articular
functionality.
The aim of this studywas to evaluate the effectiveness of the application
of mesenchymal stem cells derived from inguinal adipose tissue (aMSC)
in the treatment of degenerative joint disease in the elbow, hip and
knee of the canine species.
Methods: This was a serial clinical multi-center study that included a
total of 26 healthy dogs weighting more than 15 kg, with OA docu-
mented by X-Rays and clinical ﬁndings. The joints affected were dis-
tributed in 17 hips, 4 knees and 5 elbows.
The dogs were treated with one 2 ml intra-articular injection of aMSCs
containing 30 millions of aMSC obtained by Dog-Stem® method, fol-
lowing conventional protocol for all joints.
The variables evaluated were a radiological assessment of the affected
joints (mild, moderate or severe), functional limitation (measurement
scale: 0 to 23 points), and joint mobility (measurement scale: 0 to 7
points), as well as serum hyaluronic acid (HA) and collagen type II
cleavage neoepitope (C2C) concentration.
In addition, owners completed a questionnaire on satisfaction with
treatment and the perception of pain in their pets with a visual ana-
logue scale (VAS).
All these variables were measured at baseline (just before applying the
treatment) and one, three and six months after treatment.
Results: The average age and weight of the patients were 58±40
months (age range: 8-135 months), and 35,1±14,0 kg (weigh range:
18,1-66,2 kg), respectively. There were 17 males and 9 females, 10 of
them were spayed.
The radiographic grade of OA remained constant over time.
With respect to other parameters like functional limitation, joint
mobility, owner satisfaction, VAS and serum C2C and HA (Figure 1 and
2, respectively), there was improvement from the ﬁrst month to six
months after treatment. No adverse effects were observed during the
study.
Conclusions: The application of a single intra-articular injection of
aMSCs, demonstrate improvement of the clinical signs and symptoms
of OA, decreasing pain and improving joint function with no adverse
effects and no radiographic changes, with an increase in HA and a
decrease in the C2C serum levels. Stem cells are established as a safe
and promising therapeutic option besides the capacity to regenerate
damaged tissues and organs and there are great expectations for the
future.
